The trigger is one small injection at the end of stimulation — and most of the cycle outcome rides on it. The talk walks through HCG, GnRH agonist, dual and double trigger strategies, the Vienna consensus 80-95% oocyte yield target, and the practical decisions that connect trigger choice to oocyte maturation in real protocols.
HCG remains the workhorse trigger but extends LH-like activity over 6-7 days, driving the progesterone surge in fresh cycles. Agonist trigger gives a much shorter LH peak (24-28 hours) and a steep luteal-phase drop — needs rescue if transferring fresh. Dual trigger (agonist + HCG) recovers oocyte maturation in cases with low yield-per-follicle ratio. The Vienna consensus oocyte-yield target of 80-95% of antral follicles is a usable lab quality marker.
Match trigger choice to the cycle plan: HCG for fresh transfer with full luteal-phase support; agonist trigger for freeze-all and OHSS risk; dual trigger when prior cycle showed a low yield-to-follicle ratio. Audit your lab against the 80-95% Vienna target and identify whether deviations come from stimulation, trigger timing or aspiration technique.
Empty follicle syndrome can present even with a correctly administered trigger — check LH stick or progesterone in suspicious cases. Trigger timing affects maturation more than dose at modern doses. HMG-derived LH activity does not match recombinant LH or HCG one-to-one.
The dual trigger (GnRH agonist + low-dose hCG) combines the advantages: a physiological surge and luteal-phase support. The double trigger — administering two stimuli at an interval (for example, 40 and 34 hours before retrieval) — is used when the oocyte immaturity index is high, to synchronize final maturation.
The Vienna consensus sets a target benchmark of efficiency: the proportion of mature oocytes (yield) should be around 80–95% of the number of follicles ≥12–14 mm. A downward deviation is a signal to reconsider the timing, dose and type of trigger.
Timing is critical: the trigger is given when there is a sufficient number of leading follicles, and retrieval after a strictly calibrated interval matching the kinetics of meiosis resumption and cumulus expansion. An error in timing directly reduces the proportion of mature MII oocytes.
Empty follicle syndrome — the absence of oocytes when aspirating visually mature follicles — is more often related to pharmacokinetics or a trigger administration error than to true pathology. The analysis of its causes closes the logic of the lecture: the right trigger at the right time is the key to oocyte quality.
The trigger is one small injection at the end of stimulation — and most of the cycle outcome rides on it. A practical walk through trigger choice (HCG, agonist, dual, double), the Vienna consensus 80-95% oocyte yield ratio, and what each trigger does to oocyte maturation in real protocols.
Patients arrive at the clinic already having consulted ChatGPT, and regulators are reviewing the first AI ‘doctors’. What in artificial intelligence already works in reproductive medicine — from assistant avatars to embryo assessment and stimulation personalisation? A live discussion on three levels — strategy, service and clinic — with practical cases and a panel Q&A.
A Sona-Pharm grant award for specialists in infertility treatment. Applications open on 1 February 2027. Ceremony — July 2027, Stockholm, during the ESHRE meeting.
Targeted, biomarker-guided immunotropic therapy in reproductive medicine. A lecture by Kseniia Khazhylenko at the UARM Symposium 2026.
Audio: UASubtitles: UA32 min
-1.png&w=3840&q=75)
